Review paper
The clinical potential of gene editing as a tool to engineer cell‐based therapeutics
Abstract
The clinical application of ex vivo gene edited cell therapies first began a decade ago with zinc finger nuclease editing of autologous CD4 + T‐cells. Editing aimed to disrupt expression of the human immunodeficiency virus co‐receptor gene CCR5 , with the goal of yielding cells resistant to viral entry, prior to re‐infusion into the patient. Since then the field has substantially evolved with the arrival of the new editing technologies...
Paper Details
Title
The clinical potential of gene editing as a tool to engineer cell‐based therapeutics
Published Date
Jan 1, 2020
Volume
9
Issue
1
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History